September 20, 2024 – CITI PHARMA LTD has made a groundbreaking achievement by becoming Pakistan’s first exporter of nutraceutical products and multivitamins to the USA. As Pakistan’s largest Active Pharmaceutical Ingredients (API) manufacturer, CITI PHARMA announced the formal ground launch of its nutraceutical products after receiving FDA approval in September 2024. The company will now export FDA-approved nutraceutical products in several categories, including:

  • Fertility
  • Weight management
  • Stress and mood boosters
  • Hair and skin care
  • Joint and muscle pain relief

This landmark FDA approval highlights Citi Pharma’s compliance with rigorous international quality standards, enabling it to enter the highly competitive U.S. market. CITI PHARMA’s product line features a diverse range of forms such as tablets, capsules, powder sachets, syrups, ointments, gels, injections, infusions, and solutions, catering to both local and global markets.

What sets CITI PHARMA apart is its commitment to providing top-quality, pure, and effective products. The company ensures the highest standard of care in every product it offers. Leading this remarkable initiative is CEO Mr. Rizwan, whose vision and dedication have been instrumental in establishing CITI PHARMA as a game-changer in the industry.

The financial impact of this FDA approval is expected to be significant, with CITI PHARMA projecting to generate an additional $3 million in annual revenue from the U.S. market, with profit margins ranging from 25% to 30%. This approval not only strengthens the company’s credibility but also positions CITI PHARMA as an emerging global player, which could potentially lead to further international partnerships and investments.

The company successfully completed its first shipment with a payment of USD 109,500.

This achievement underscores the growing presence of Pakistan in the global pharmaceutical industry and is a testament to the country’s increasing ability to meet stringent international standards.

Source: PSX

LEAVE A REPLY

Please enter your comment!
Please enter your name here